SynthesisFrontiers in endocrinology2026
Efficacy and safety of Buyang Huanwu Decoction combined with α-lipoic acid for diabetic peripheral neuropathy: a systematic review with in-depth heterogeneity deconstruction and methodological appraisal.
Synthesis in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Diabetic peripheral neuropathy (DPN) is a common diabetes complication. Buyang Huanwu Decoction (BYHWD) combined with α-lipoic acid (ALA) is used clinically, but evidence consistency and heterogeneity sources remain unexplored. Objective: To evaluate efficacy/safety of BYHWD+ALA for DPN and deconstruct heterogeneity via a multi-tiered framework. Methods: We searched PubMed, Web of Science, EMbase, Cochrane Library, CNKI, Wanfang, VIP, and CBM up to December 2025 for RCTs. Two reviewers independently screened studies, extracted data, and assessed risk of bias (Cochrane tool). Meta-analysis used RR (dichotomous) and SMD (continuous) with 95% CI. Heterogeneity (I²) was explored through subgroup analysis, sensitivity analysis, meta-regression, and descriptive synthesis. Results: Twelve RCTs (926 patients) were included. BYHWD+ALA significantly improved overall response rate (RR = 1.24, 95%CI 1.17-1.32; I²=0%) and TCM syndrome scores (SMD=-0.76, 95%CI -0.98 to -0.54). For nerve conduction velocity (NCV), fundamental heterogeneity emerged (I²>92%). A five-tiered analysis revealed that only peroneal nerve motor NCV showed a robust improvement trend (SMD = 1.01, 95%CI 0.48-1.54), though heterogeneity remained high (I²=92%). Heterogeneity sources included non-standardized NCV measurement and complex intervention-patient matching. Oxidative stress markers (SOD, MDA, T-AOC) trended favorably; HbA1c and adverse events did not differ between groups. Conclusion: BYHWD+ALA safely improves subjective DPN symptoms, but NCV evidence is too heterogeneous to draw reliable quantitative conclusions. This study provides a methodological framework for deconstructing heterogeneity and guides future standardized research. Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=1267606, identifier CRD420251267606.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.